Phaseline

Companies › Foresee Pharmaceuticals

Foresee Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Mirivadelgat
Selective aldehyde dehydrogenase 2 (ALDH2) activator
ALDH2Phase 2Group 3 Pulmonary HypertensionFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06475781MirivadelgatPhase 2Group 3 Pulmonary HypertensionCardiovascularFeb 2028

Targets

ALDH2 (1)

Companies with the same targets

–

Companies built like this

Tectonic Operating Company CuraSen Therapeutics Neurimmune Seismic Pharmaceuticals Operations Nyrada

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.